P
Procyrion
Developing catheter-based circulatory support technologies to address a significant unmet clinical need for CHF patients
About Procyrion
Procyrion is a medical device company based in Houston, Texas, that is developing a novel treatment for patients with heart failure. The company's flagship product, Aortix™, is a catheter-deployed circulatory assist device designed to be minimally invasive. It is specifically targeted at the significant portion of heart failure patients who are no longer responsive to medical therapy.
The Aortix™ device is a small, powerful pump mounted on a self-expanding anchor. It is placed in the descending thoracic aorta via a catheter, a procedure that can be performed in a catheterization laboratory. Once in place, the device works by reducing the afterload on the heart, which is the resistance the heart must overcome to pump blood. This allows the heart to rest and heal, while simultaneously improving blood flow to vital organs like the kidneys.
The company is focused on addressing the unmet needs of a large and growing patient population. Heart failure is a chronic and progressive disease that affects millions of people worldwide. Procyrion's technology has the potential to provide a new treatment option for these patients, improving their quality of life and reducing the high costs associated with their care. The company is currently in the clinical trial phase, gathering data to support the safety and efficacy of its device.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- Houston, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 31.5/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Cardiology and cardiovascular, Catheters, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Feb 2024 | $58M | $231M | Fannin Partners · BlueBird Merchant Ventures | ↗ |
| SERIES DOther financing | Jul 2019 | $30M | $120M | BlueBird Merchant Ventures | — |
Growth signals
Latest recorded traffic for Procyrion is 2.4K monthly website visits, up 4.3% over the last three months. Procyrion's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Houston Angel Network
Scientific Health Development Partners
Series B and later4 investors entered at this stage
Jefferson River Capital- AQAquinas
BlueBird Merchant Ventures
Fannin Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Procyrion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Procyrion’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.